Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hidenobu Ishii

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Nihon Rinsho. Japanese Journal of Clinical Medicine|November 11, 2009
[Bronchial asthma]Hisamichi Aizawa, Tomomi Sekizuka, Hidenobu Ishii
Investigational New Drugs|August 13, 2020
Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapyHidenobu Ishii, Koichi Azuma, Akihiko Kawahara, et al.
Oncology Letters|November 4, 2014
Predictive factors in patients with EGFR mutation-negative non-small cell lung cancer treated with erlotinibHidenobu Ishii, Koichi Azuma, Kazuhiko Yamada, et al.
Annals of Thoracic and Cardiovascular Surgery : Official Journal of the Association of Thoracic and Cardiovascular Surgeons of Asia|March 29, 2013
Metachronous bilateral pulmonary metastases from cancer of the ampulla duodeniMotohisa Kuwahara, Hidenobu Ishii, Kazuya Naritomi, et al.
Investigational New Drugs|January 23, 2021
Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapyNorikazu Matsuo, Koichi Azuma, Takashi Kojima, et al.
BMJ Open Respiratory Research|January 27, 2017
Accuracy of transbronchial biopsy as a rebiopsy method for patients with relapse of advanced non-small-cell lung cancer after systemic chemotherapyHidenobu Ishii, Koichi Azuma, Kazuhiko Yamada, et al.
Internal Medicine (Tokyo, Japan)|September 4, 2024
Thoracic Angiosarcoma Arising from Chronic Tuberculous PyothoraxTakayuki Horii, Jun Sasaki, Hidenobu Ishii, et al.
Cancer Management and Research|December 21, 2022
Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain MetastasesYoshimasa Shiraishi, Takayuki Shimose, Yuko Tsuchiya-Kawano, et al.
Oncotarget|September 4, 2015
Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samplesHidenobu Ishii, Koichi Azuma, Kazuko Sakai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 11, 2014
Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancerHidenobu Ishii, Koichi Azuma, Akihiko Kawahara, et al.
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Nihon Rinsho. Japanese Journal of Clinical Medicine|November 11, 2009
[Bronchial asthma]Hisamichi Aizawa, Tomomi Sekizuka, Hidenobu Ishii
Investigational New Drugs|August 13, 2020
Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapyHidenobu Ishii, Koichi Azuma, Akihiko Kawahara, et al.
Oncology Letters|November 4, 2014
Predictive factors in patients with EGFR mutation-negative non-small cell lung cancer treated with erlotinibHidenobu Ishii, Koichi Azuma, Kazuhiko Yamada, et al.
Annals of Thoracic and Cardiovascular Surgery : Official Journal of the Association of Thoracic and Cardiovascular Surgeons of Asia|March 29, 2013
Metachronous bilateral pulmonary metastases from cancer of the ampulla duodeniMotohisa Kuwahara, Hidenobu Ishii, Kazuya Naritomi, et al.
Investigational New Drugs|January 23, 2021
Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapyNorikazu Matsuo, Koichi Azuma, Takashi Kojima, et al.
BMJ Open Respiratory Research|January 27, 2017
Accuracy of transbronchial biopsy as a rebiopsy method for patients with relapse of advanced non-small-cell lung cancer after systemic chemotherapyHidenobu Ishii, Koichi Azuma, Kazuhiko Yamada, et al.
Internal Medicine (Tokyo, Japan)|September 4, 2024
Thoracic Angiosarcoma Arising from Chronic Tuberculous PyothoraxTakayuki Horii, Jun Sasaki, Hidenobu Ishii, et al.
Cancer Management and Research|December 21, 2022
Forthcoming Phase II Study of Durvalumab (MEDI4736) Plus Chemotherapy for Small Cell Lung Cancer with Brain MetastasesYoshimasa Shiraishi, Takayuki Shimose, Yuko Tsuchiya-Kawano, et al.
Oncotarget|September 4, 2015
Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samplesHidenobu Ishii, Koichi Azuma, Kazuko Sakai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 11, 2014
Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancerHidenobu Ishii, Koichi Azuma, Akihiko Kawahara, et al.
Pageof 6